Serb`s Amversio (Betaine Anhydrous) Receives Approval in Europe
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products...
Serb SA's Amifampridine Serb (amifampridine) Receives Approval in Europe
SERB SAS` Voraxaze (glucarpidase) Receives Approval in Europe
LONDON, Nov. 30, 2021n/PRNewswire/ -- SERB and BTG Specialty Pharmaceuticals today announced nthat the Committee for Medicinal Products for Human Use (CHMP) of the nEuropean Medicines Agency (EMA) adopted a positive opinion recommending a marketing authorisation for Voraxaze®n(glucarpidase) to reduce toxic plasma methotrexate concentration in nadults and children (aged 28 days and older) with delayed methotrexate nelimination or at risk of methotrexate toxicity.
SERB Specialty Pharmaceuticals has purchased BTG Specialty Pharmaceuticals, a division of Boston Scientific that develops treatments with critical conditions, for an undisclosed fee.